Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2655
Source ID: NCT00141492
Associated Drug: Androgel (Testosterone Gel)
Title: Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes|Hypogonadism
Interventions: DRUG: Androgel (testosterone gel)
Outcome Measures:
Sponsor/Collaborators: Sponsor: Solvay Pharmaceuticals
Gender: MALE
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment:
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
Start Date: 2004-10
Completion Date: 2007-06
Results First Posted:
Last Update Posted: 2015-01-21
Locations: Site 58, Birmingham, Alabama, United States|Site 67, Calera, Alabama, United States|Site 54, Mobile, Alabama, United States|Site 16, Phoenix, Arizona, United States|Site 35, Anaheim, California, United States|Site 23, Concord, California, United States|Site 55, La Jolla, California, United States|Site 8, Los Gatos, California, United States|Site 12, Mission Viejo, California, United States|Site 1, Torrance, California, United States|Site 25, Glastonbury, Connecticut, United States|Site 13, Ft. Lauderdale, Florida, United States|Site 43, Jacksonville, Florida, United States|Site 33, Ocala, Florida, United States|Site 27, Tampa, Florida, United States|Site 21, West Palm Beach, Florida, United States|Site 7, Atlanta, Georgia, United States|Site 26, Columbus, Georgia, United States|Site 29, Boise, Idaho, United States|Site 45, Idaho Falls, Idaho, United States|Site 51, Chicago, Illinois, United States|Site 32, Des Moines, Iowa, United States|Site 5, Baton Rouge, Louisiana, United States|Site 70, Baltimore, Maryland, United States|Site 9, Springfield, Massachusetts, United States|Site 48, Watertown, Massachusetts, United States|Site 19, Detroit, Michigan, United States|Site 61, Livonia, Michigan, United States|Site 40, Tupelo, Mississippi, United States|Site 65, Chesterfield, Missouri, United States|Site 15, Kansas City, Missouri, United States|Site 41, Omaha, Nebraska, United States|Site 34, Las Vegas, Nevada, United States|Site 24, Jersey City, New Jersey, United States|Site 49, Buffalo, New York, United States|Site 71, New York, New York, United States|Site 44, Fayetteville, North Carolina, United States|Site 28, Morehead City, North Carolina, United States|Site 60, Morehead City, North Carolina, United States|Site 31, Portland, Oregon, United States|Site 3, Portland, Oregon, United States|Site 68, Altoona, Pennsylvania, United States|Site 4, Bala Cynwyd, Pennsylvania, United States|Site 64, Carlisle, Pennsylvania, United States|Site 38, Lansdale, Pennsylvania, United States|Site 46, Shippensburg, Pennsylvania, United States|Site 14, Greer, South Carolina, United States|Site 20, Arlington, Texas, United States|Site 11, Dallas, Texas, United States|Site 10, Houston, Texas, United States|Site 18, Houston, Texas, United States|Site 2, Houston, Texas, United States|Site 36, Houston, Texas, United States|Site 39, Houston, Texas, United States|Site 42, Houston, Texas, United States|Site 47, Houston, Texas, United States|Site 53, Houston, Texas, United States|Site 62, Houston, Texas, United States|Site 63, Houston, Texas, United States|Site 69, Houston, Texas, United States|Site 6, Humble, Texas, United States|Site 30, La Porte, Texas, United States|Site 66, Midland, Texas, United States|Site 37, San Antonio, Texas, United States|Site 56, Sugarland, Texas, United States|Site 57, Sugarland, Texas, United States|Site 52, Ogden, Utah, United States|Site 17, Salt Lake City, Utah, United States|Site 22, Salem, Virginia, United States|Site 50, Seattle, Washington, United States
URL: https://clinicaltrials.gov/show/NCT00141492

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D176 Testosterone small molecule DB00624 Details